http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EA-201201220-A1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-185 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-12 |
| filingDate | 2012-10-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2014-04-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EA-201201220-A1 |
| titleOfInvention | PHARMACEUTICAL COMPOSITION, HAVING METABOLIC, ANTI-PATH, RETINOPROTECTIVE ACTION (OPTIONS) |
| abstract | The invention relates to the field of medicine, namely, ophthalmology. The present invention is the creation of an effective pharmaceutical composition with metabolic, anti-cataract, retinoprotective effect due to the fact that the pharmaceutical composition contains taurine and additionally contains minerals, as well as isotopes. When implementing the claimed pharmaceutical formulations in practice, there will be an increase in the therapeutic effect and speed of the onset of the therapeutic effect without an increase in the concentration of taurine, as well as an increase in the stability of the pharmaceutical composition with taurine during the shelf life. |
| priorityDate | 2012-10-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
| Predicate | Subject |
|---|---|
| isDiscussedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419489743 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID1123 |
Total number of triples: 17.